CAGT hero 2

Leaders in Developing and Applying Genomic Technologies

The Genomic Revolution promises the discovery of targeted approaches for treating disease. Innovations like CRISPR-based genome editing and comprehensive epigenomic profiling can inform, streamline and accelerate drug target discoveries, but piecing together this complex puzzle requires an interdisciplinary approach.

The Center for Advanced Genomic Technologies (CAGT) has assembled a team of world-leading engineers, scientists and physicians to integrate these technologies to unravel disease biology and discover new drug targets. By working together, we will catalyze a more robust biotechnology enterprise.

In the News

Charlie Gersbach

April 28, 2022 | Gilbert Family Foundation

Gersbach awarded $1.2M Gilbert Family Foundation grant for Gene Therapy Initiative

The Gilbert Family Foundation, announced more than $18 million in grants to fund a new three-year campaign as part of the organization’s Gene Therapy Initiative.

This is a rendering of mRNA, which was successfully used by Emory researchers to modulate gene expression in animal models. The finding could have application for several diseases, including cancer.

April 20, 2022 | Emory News Center

Duke, Emory collaboration successfully uses mRNA to activate genes

What if we could regulate the way genes are expressed? That question has long intrigued researchers, and a new collaboration between Duke and Emory University helps narrow the knowledge gap by showing for the first time that mRNA can be used to activate genes in animals.

IV line with machine in view

March 31, 2022 | Duke Health News

Cancer Repair Mechanism Could Be Potential Drug Target

Disrupting a key cell repair mechanism could extend the benefit of targeted therapies